News & Updation
Best Paper Awards
World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.
Best Article of current issue
Download Article : Click here
A COMPARATIVE STUDY ON TOLERABILITY AND QUALITY OF LIFE OF COLORECTAL CANCER PATIENTS ON FOLFOX AND CAPOX REGIMEN
*Fouziya Begum, Ayesha Saffura, Vunnamatla Manish and K. Jigeesha Reddy
Objective: The study aimed to compare the Tolerability and Quality of life of Colorectal Cancer patients on FOLFOX (leucovorin, 5fluorouracil and oxaliplatin) and CAPOX (capecitabine and oxaliplatin) regimens. Methodology: A total of 102 colorectal cancer patients On FOLFOX and CAPOX regimens were prospectively analysed for 6months. The data was gathered from patients’ Case sheets and by interviewing the patients. The tolerability and Quality of life of these two regimens were compared by using the CTCAE grading system and two functional questionnaires Viz., EORTC QLQ C-30, and FACT-C version 4 respectively. Statistical tools like the independent sample t-test and Chi-square test were applied to the data using SPSS Software. Results: Among 102 patients, 52(50.9%) were on FOLFOX and 50(49.01%) were on the CAPOX regimen. male (64.7%) patients were predominant compared to female (35.3%) patients. CTCAE Grade3 peripheral sensory neuropathy, Diarrhoea, Vomiting and treatment discontinuation were significantly higher in CAPOX compared to FOLFOX. A Significantly High EORTC QLQ C-30 Global health quality of life and a higher level of functioning were observed in FOLFOX compared to the CAPOX group. However, higher levels of problems or symptomatology were observed in CAPOX. There is a significantly higher FACT-C total score was observed in the FOLFOX group, indicating higher quality of life in FOLFOX. Conclusion: The Tolerability of FOLFOX was higher compared to CAPOX. Both EORTC QLQ-C30 and FACT C scores concluded better quality of life in FOLFOX compared to CAPOX. Moreover, Treatment discontinuation was higher in the CAPOX group.[Full Text Article]